Russell Abberley

ABPI has appointed Russell Abberley as Acting President

The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley as Acting President.

Abberley, who is General Manager of Amgen UK and Ireland, has over 25 years of life sciences industry experience across a range of geographies. He has been serving on the ABPI Board for the past four years and was elected to the role of ABPI Vice-President in May.

Prior to taking on his current role at Amgen, Abberley held the position of Business Unit Director, General Medicine and Biosimilars at the company.

He has served in multiple roles at AstraZeneca, including Business Unit Director, Respiratory, Inflammation and Autoimmune, and has held a variety of positions at MSD and the Schering-Plough Research Institute.

Commenting on his latest venture, Abberley said: “I am delighted to take on the role of Acting President. Our industry represents a real force for good in the UK – developing, manufacturing and driving access to innovative medicines for patients and working with the NHS to improve the nation’s health and well-being… Key for me will be ensuring the UK maintains and improves its international competitiveness as a place to research, develop and launch innovative medicines.”

Abberley will take up the role on an interim basis, with the ABPI Board set to elect a new President in early 2025.

Richard Torbett, ABPI Chief Executive said: “Russell is a prominent and hugely respected industry leader who has already contributed a great deal to the wider success of the UK’s health and life sciences community. He was the natural choice to step in as Acting ABPI President, and I look forward to working with him even more closely.”